Navigation Links
Abaxis Reports Financial Performance for the First Quarter of Fiscal 2012
Date:7/28/2011

Administration clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Abaxis' intellectual property or claims of infringement of intellectual property asserted by third parties, risks related to condition of the United States economy and other risks detailed under "Risk Factors" in Abaxis' Annual Report on Form 10-K for the fiscal year ended March 31, 2011 and Abaxis' other periodic reports filed from time to time with the United States Securities and Exchange Commission.  Forward-looking statements speak only as of the date the statements were made.  Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.Financial Tables on Following PagesABAXIS, INC.Condensed Consolidated Statements of Income(In thousands, except per share data)(Unaudited)Three Months EndedJune 30,20112010Revenues

$
36,003

$
34,953Cost of revenues

16,780

15,169Gross profit

19,223

19,784Operating expenses:Research and development

3,454

3,078Sales and marketing

9,152

8,633General and administrative

3,419

2,124Total operating expenses

16,025

13,835Income from operations

3,198

5,949Interest and other income (expense), net

294

(105)Income before income tax provision

3,492

5,844Income tax provision

1,278

2,264Net income

$
2,214

$
3,580Net income per share:  Basic net income per share

$
.10

$
.16  Diluted net income per share

$
.10

$
.16Shares used in the calculation of net income per share:  Weighted average common shares outstanding -
'/>"/>

SOURCE Abaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Abaxis to Report First Quarter Fiscal Year 2012 Financial Results Thursday, July 28, 2011
2. Abaxis to Present at Jefferies 2011 Global Healthcare Conference
3. Abaxis to Present at ThinkEquitys Second Annual Healthcare Conference
4. Abaxis Receives Presidential "E" Award for Exports
5. Abaxis, Inc. Awarded $650,000 from Kansas Bioscience Authority
6. Abaxis, Inc. to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
7. Abaxis Appoints Vernon Altman to Board of Directors
8. Abaxis to Report Fourth Quarter and Fiscal Year 2011 Financial Results Thursday, April 28, 2011
9. Abaxis, Inc. to Present at the 10th Annual Needham Healthcare Conference
10. Abaxis, Inc. to Present at RBC Capital Markets Healthcare Conference
11. Abaxis Reports Financial Performance With Record Sales for the Third Quarter of Fiscal 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... July 23, 2014 /PRNewswire-iReach/ -- Top Staten Island Pediatrician ... his feedback on article, which discusses tips for parents about ... According to US News ... death among American children aged 1 to 4, and can ... One expert in the article says that watching a ...
(Date:7/23/2014)... July 23, 2014 Inovio Pharmaceuticals, ... results from its randomized, double-blind, placebo-controlled phase ... biopsy-proven cervical intraepithelial neoplasia 2/3 (CIN2/3) associated ... 18. Treatment with VGX-3100, Inovio,s HPV16/18-specific immunotherapy, ... CIN1 or no disease, meeting the study,s ...
(Date:7/23/2014)... , July 23, 2014  The management team ... ) will hold a conference call on July ... second quarter ended June 30, 2014.  The call ... 2014Time: , 8:30 am EDTDial-in numbers: , Toll ... (412) 317-0790Webcast (live & archive): , www.columbialabs.com ...
Breaking Medicine Technology:Premier Staten Island Pediatrician Dr. Michael Gabriel Comments On Article Discussing Pool Safety Tips for Parents 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 3Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 4Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 5Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2
... , PALO ALTO, Calif., Dec. 2 ... 25, 2009, Varian, Inc. filed with the U.S. Securities and Exchange ... ended October 2, 2009. This Annual Report may be accessed ... and "SEC Filings," and then on "10-K" in the table shown. ...
... , ST. LOUIS, Dec. 2 KV Pharmaceutical Company ... an employment agreement with Interim President and Chief Executive Officer ... 2011. Mr. Van Vliet has served as Interim President and ... provides continuity of senior leadership as the Company seeks to ...
Cached Medicine Technology:KV Pharmaceutical Enters Into Employment Agreement with Interim President and Chief Executive Officer David A. Van Vliet 2
(Date:7/23/2014)... ( FXS ) is a genetic disorder that causes ... autistic spectrum, as well as cognitive deficits. It is ... the most common cause of autism. , Now biomedical ... a study that sheds light on the ... (July 23) in the Journal of Neuroscience , ...
(Date:7/23/2014)... Kathleen Doheny HealthDay Reporter ... surgery appears to have an additional side benefit -- ... to a new study. The study found that ... reported having incontinence prior to the procedure. After surgery, ... improved or disappeared, said study researcher Dr. Leslee Subak, ...
(Date:7/23/2014)... the genome resulting from a combination of genetic modifications ... weak predispositions to developing certain kinds of cancer; in ... throughout our lifetime. Although the genetic origins of cancers ... not able to measure the role of non-coding regions ... from the University of Geneva (UNIGE), by studying tissues ...
(Date:7/23/2014)... 2014 A therapy combining salmon fibrin injections into ... into the brain restored voluntary motor function impaired by ... Center have found. , In a study on rodents, ... turning back the developmental clock in a molecular pathway ... and providing a scaffold so that neuronal axons at ...
(Date:7/23/2014)... Recently, Agebc.com has launched its new collection of ... a promotion of wedding dresses. According to a representative ... end of this month. , The beautiful wedding dresses ... mermaid, ball-gown, empire, and more. Agebc.com is a well-known ... for women, and the company is devoted to providing ...
Breaking Medicine News(10 mins):Health News:Study links enzyme to autistic behaviors 2Health News:Study links enzyme to autistic behaviors 3Health News:Weight Loss Surgery May Help Ease Urinary Incontinence 2Health News:Weight Loss Surgery May Help Ease Urinary Incontinence 3Health News:Genetics of cancer: Non-coding DNA can finally be decoded 2Health News:Gene inhibitor, salmon fibrin restore function lost in spinal cord injury 2Health News:Agebc.com Launched Its New Collection of Wedding Dresses 2
... ... beings need music as a form of release and expression, and now it has been ... ... stressors, stimuli, and distractions in this world, it can be difficult for the average person ...
... Huge ... ... Almac has addressed ongoing industry developments by greatly expanding their capacity in the New ... in the pharmaceutical industry, specifically the growing demand for biologics. Biologics, which are ...
... ... announced today it has acquired Canterbury International, a privately-held company based ... furnishings. The Verdin Company, based in Cincinnati, Ohio, is recognized ... and clock towers, glockenspiels, and other musical instruments.,Canterbury International, a leading ...
... ... and Profitability. , ... Manasquan, NJ, USA (PRWEB) June 21, 2010 -- Marketers with sufficient insight to estimate ... untapped profit potential, according to the 2010 Lenskold Group / emedia Lead ...
... ... industry. Anyone who can understand this contradiction, will understand the sense of urgency related to ... now, keeping BP’s oil spill and the effects of it in mind. , ... (PRWEB) June 20, 2010 -- BP’s oil ...
... ... profession will come together to share knowledge and explore innovations in one of the most ... ... unique conferences offering high-quality scientific programs, which broaden perspectives by exploring the latest innovations in ...
Cached Medicine News:Health News:Reinvent your Mental State With Brainwave Entrainment Relaxation Music 2Health News:Reinvent your Mental State With Brainwave Entrainment Relaxation Music 3Health News:Reinvent your Mental State With Brainwave Entrainment Relaxation Music 4Health News:Almac's US Headquarters Will Address Capacity Demand for Clinical Supplies 2Health News:The Verdin Company Acquires Canterbury International, an industry leader in architectural site furnishings for over 50 years 2Health News:The Verdin Company Acquires Canterbury International, an industry leader in architectural site furnishings for over 50 years 3Health News:Lead Generation Marketing ROI Study Released 2Health News:Lead Generation Marketing ROI Study Released 3Health News:Lead Generation Marketing ROI Study Released 4Health News:Wind turbines harmful for the environment and public health 2Health News:The 2nd Future Trends in Implantology International Dental Conference 2
Diamond Filter Tips play a critical role in preventing aerosol-borne contamination. Also available sterilized (no need to autoclave) and certified free of detectable RNase, DNase, DNA, RNA, and prote...
10 L, Racked, Pre-sterilized, 96 tips/rack Recommended for 2, 5 and 10 L pipettes....
... are ideal for PCR and ... any work where aerosol contamination ... for pipetting DNA/RNA solutions, infectious ... For applications requiring absolute sterility, ...
Avant E-Z Rack Premium Low Binding 10 l Pipet Tips are accurate, contamination free, and allow quantitative transfer of your samples without relying on silicone....
Medicine Products: